Advertisement
Advertisement

ALLR

ALLR logo

Allarity Therapeutics, Inc. Common Stock

1.30
USD
Sponsored
-0.02
-1.52%
Jun 24, 15:59 UTC -4
Closed
exchange

After-Market

1.32

+0.02
+1.92%

ALLR Earnings Reports

Positive Surprise Ratio

ALLR beat 9 of 14 last estimates.

64%

Next Report

Date of Next Report
Aug 15, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/
-$0.25
Implied change from Q1 26 (Revenue/ EPS)
-100.00%
/
+47.06%
Implied change from Q2 25 (Revenue/ EPS)
--
/
+66.67%

Allarity Therapeutics, Inc. Common Stock earnings per share and revenue

On May 15, 2026, ALLR reported earnings of -0.17 USD per share (EPS) for Q1 26, beating the estimate of -0.22 USD, resulting in a 24.24% surprise. Revenue reached 25.00 thousand, compared to an expected --, with a 0.00% difference. The market reacted with a +5.93% price change (close before vs. close after earnings).
Looking ahead to Q2 26, -- analysts forecast an EPS of -0.25 USD, with revenue projected to reach -- USD, implying an increase of 47.06% EPS, and decrease of -100.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Vistagen Therapeutics, Inc. Common Stock
Report Date
Jun 15, 2026 For Q4 26
Estimate
-$0.34
Actual
-$0.37
Surprise
-7.75%
logo
enGene Therapeutics Inc. Common Stock
Report Date
Jun 15, 2026 For Q2 26
Estimate
-$0.47
Actual
-$0.43
Surprise
+10.32%
logo
Prenetics Global Limited Class A Ordinary Share
Report Date
Jun 10, 2026 For Q1 26
Estimate
-$1.10
Actual
-$1.61
Surprise
-45.36%
logo
Anixa Biosciences, Inc.
Report Date
Jun 10, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.07
Surprise
+21.61%
FAQ
For Q1 2026, Allarity Therapeutics, Inc. Common Stock reported EPS of -$0.17, beating estimates by 24.24%, and revenue of $25.00K, 0% as expectations.
The stock price moved up 5.93%, changed from $1.35 before the earnings release to $1.43 the day after.
The next earning report is scheduled for Aug 15, 2026.
Based on -- analysts, Allarity Therapeutics, Inc. Common Stock is expected to report EPS of -$0.25 and revenue of -- for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement